오토인젝터 시장 규모, 점유율, 예측 및 동향 분석 : 유형, 기술, 용도, 유통 채널, 투여 경로, 최종 사용자별 - 예측(-2031년)
Autoinjectors Market Size, Share, Forecast, & Trends Analysis by Type, Technology, Application, Distribution, Route of Administration, End User - Global Forecast to 2031
상품코드 : 1576509
리서치사 : Meticulous Research
발행일 : On Demand Report
페이지 정보 : 영문
 라이선스 & 가격 (부가세 별도)
US $ 4,175 ₩ 6,194,000
PDF & Excel (Single User License) help
PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 파일 내 텍스트 등의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF·Excel 이용 범위와 동일합니다.
US $ 5,875 ₩ 8,716,000
PDF & Excel (Multi User License) help
PDF & Excel 보고서를 동일 기업내 5명까지 이용할 수 있는 라이선스입니다. 파일 내 텍스트 등의 Copy & Paste 가능합니다. 5부까지 인쇄 가능하며 인쇄물의 이용 범위는 PDF·Excel 이용 범위와 동일합니다.
US $ 7,875 ₩ 11,684,000
PDF & Excel (Global Site License) help
PDF & Excel 보고서를 동일 기업 & 자회사의 모든 분이 이용할 수 있는 라이선스입니다. 파일 내 텍스트 등의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF·Excel 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

오토인젝터 시장은 2024-2031년간 8.3%의 연평균 복합 성장률(CAGR)로 성장하여 2031년 37억 6,000만 달러에 달할 것으로 예상됩니다.

본 보고서는 광범위한 2차 및 1차 조사, 시장 시나리오에 대한 심층 분석을 통해 주요 시장 성장 촉진요인, 억제요인, 과제 및 기회 분석으로 구성되어 있습니다. 오토인젝터 시장의 성장은 전 세계 질병 부담 증가, 약물 자가 투여 선호, 첨단 오토인젝터 개발로 인해 발생합니다. 그러나 오토인젝터 대체품의 가용성, 높은 비용, 바늘에 의한 손상 우려로 인해 시장 성장이 억제되고 있습니다.

또한, 재택의료에 대한 수요 증가와 주요 기업들의 파트너십 및 협력 관계 확대는 시장 성장의 기회를 창출할 것으로 예상됩니다. 그러나 신흥국의 자가주사기 사용에 대한 인식 부족과 의료 접근성이 제한적이라는 점은 자가주사기 시장의 큰 과제입니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 시장 인사이트

제5장 오토인젝터 시장 평가 : 유형별

제6장 오토인젝터 시장 평가 : 투여 경로별

제7장 오토인젝터 시장 평가 : 기술별

제8장 오토인젝터 시장 평가 : 용도별

제9장 오토인젝터 시장 평가 : 유통 채널별

제10장 오토인젝터 시장 평가 : 최종사용자별

제11장 오토인젝터 시장 평가 : 지역별

제12장 경쟁 분석

제13장 기업 개요(사업 개요, 재무 개요, 제품 포트폴리오, 전략 전개 상황, SWOT 분석*).

(주 : SWOT 분석은 주요 5개사에 대해 기재)

제14장 부록

LSH
영문 목차

영문목차

Autoinjectors Market Size, Share, Forecast, & Trends Analysis by Type (Disposable, Reusable, Wearable), Technology (Manual, Automatic), Application (Arthritis, Diabetes, Osteoporosis), Distribution, Route of Administration, End User-Global Forecast to 2031

The autoinjectors market is projected to reach $3.76 billion by 2031 at a CAGR of 8.3% from 2024 to 2031.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the autoinjectors market is driven by the rising disease burden globally, the preference for self-administration of drugs, and the development of advanced autoinjectors. However, the availability of alternatives to autoinjectors, their high cost, and concerns regarding needlestick injury are restraining the market's growth.

Furthermore, the rising demand for home healthcare and growing partnerships and collaborations by key market players are expected to generate market growth opportunities. However, lack of awareness about the usage of autoinjectors in developing countries and limited access to healthcare in emerging countries are major challenges in the autoinjectors market.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry in the past three to four years. The key players operating in the autoinjectors market are Becton, Dickinson and Company (U.S.), Ypsomed AG (Switzerland), SHL Medical (Switzerland), Recipharm AB (Sweden), Owen Mumford Limited (U.K), Halozyme, Inc. (U.S.), AstraZeneca (U.K.), Teva Pharmaceutical Industries Ltd. (Israel), Solteam Incorporation Co., Ltd. (China), Gerresheimer AG (Germany), West Pharmaceutical Services, Inc. (U.S.), Bayer AG (Germany), and Union Medico ApS. (Denmark).

Among all the autoinjector types studied in this report, the smart autoinjectors segment is projected to register the highest CAGR of 9.7% during the forecast period. The high CAGR of the segment is attributed to the benefits of smart autoinjectors, technological advancements in smart autoinjectors, and the rise in digitized drug delivery. Digital drug delivery has shown improved patient outcomes in multiple drug treatments. In May 2021, Phillips-Medisize, LLC (U.S.), a company specializing in drug delivery, diagnostic, and MedTech devices, introduced the Aria Smart Autoinjector platform to unlock innovation, differentiation, and sustainability in the digital drug-delivery device market.

Among all the routes of administration studied in this report, in 2024, the subcutaneous segment is expected to account for a larger share of the autoinjectors market. The segment's larger share can be attributed to the rising number of newly launched drugs for subcutaneous self-administration and the higher adoption due to cost-effectiveness.

Among all the technologies studied in this report, in 2024, the manual autoinjector segment is expected to account for the larger share of the autoinjectors market. The larger market share can be attributed to the high adoption of manual autoinjectors due to their lower prices than automatic autoinjectors and easy accessibility in the distribution channel.

Among all the applications studied in this report, in 2024, the diabetes segment is expected to account for the largest share of the autoinjectors market. The segment's larger share can be attributed to the high burden of diabetes globally coupled with patient inclination towards self-administration of insulin. For instance, according to the Centers for Disease Control and Prevention, as of May 2024, around 38.4 million individuals in the U.S. had diabetes (11.6% of the U.S. population).

Among all the distribution channels studied in this report, in 2024, the retail pharmacies segment is expected to account for the largest share of the autoinjectors market. The segment's large market can be attributed to its easy accessibility to autoinjectors in retail pharmacies. Retail pharmacies enable patients to choose between autoinjectors that best suit their needs as per physician recommendations.

Among all the end users studied in this report, the homecare segment is projected to register the highest CAGR of 8.8% during the forecast period. The segment's fast growth can be attributed to patients' growing preference for self-administration. Technological developments in autoinjectors, such as smart autoinjectors available in the audio and visual feedback system, enable enhanced safety for patients in home care, thereby improving patient outcomes.

An in-depth analysis of the geographical scenario of the autoinjectors market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. Asia-Pacific is projected to register the highest CAGR of 8.8% during the forecast period. The fastest growth of the market is due to rising spending on healthcare, advancing healthcare, rising preference for home care, and growing awareness among patients or caretakers regarding self-administration of drugs.

Scope of the Report:

Autoinjectors Market Assessment-by Type

Autoinjectors Market Assessment-by Route of Administration

Autoinjectors Market Assessment-by Technology

Autoinjectors Market Assessment-by End User

Autoinjectors Market Assessment-by Application

(Note: Other applications include epilepsy, oncology, anaphylaxis, migraine, and anemia.)

Autoinjectors Market Assessment-by Distribution Channel

Autoinjectors Market Assessment-by End User

(Note: Other end users include long-term care settings and military & defense)

Autoinjectors Market Assessment-by Geography

TABLE OF CONTENTS

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Insights

5. Autoinjectors Market Assessment-by Type

6. Autoinjectors Market Assessment-by Route of Administration

7. Autoinjectors Market Assessment-by Technology

8. Autoinjectors Market Assessment-by Application

9. Autoinjectors Market Assessment-by Distribution Channel

10. Autoinjectors Market Assessment-by End User

11. Autoinjectors Market Assessment-by Geography

12. Competition Analysis

13. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis*)

(Note: SWOT analysis will be provided for the top 5 companies.)

14. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기